HOWL
Price:
$2.02
Market Cap:
$88.28M
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company...[Read more]
Industry
Biotechnology
IPO Date
2021-04-30
Stock Exchange
NASDAQ
Ticker
HOWL
According to Werewolf Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.46. This represents a change of -46.04% compared to the average of -2.71 of the last 4 quarters.
The mean historical PE Ratio of Werewolf Therapeutics, Inc. over the last ten years is -16.85. The current -1.46 PE Ratio has changed 766.46% with respect to the historical average. Over the past ten years (40 quarters), HOWL's PE Ratio was at its highest in in the June 2020 quarter at 16.00. The PE Ratio was at its lowest in in the March 2021 quarter at -14.23.
Average
-16.85
Median
-6.54
Minimum
-41.99
Maximum
-1.15
Discovering the peaks and valleys of Werewolf Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 220.88%
Maximum Annual PE Ratio = -1.15
Minimum Annual Increase = -82.44%
Minimum Annual PE Ratio = -41.99
Year | PE Ratio | Change |
---|---|---|
2023 | -3.68 | 220.88% |
2022 | -1.15 | -82.44% |
2021 | -6.54 | -78.84% |
2020 | -30.89 | -26.43% |
The current PE Ratio of Werewolf Therapeutics, Inc. (HOWL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.79
5-year avg
-16.85
10-year avg
-16.85
Werewolf Therapeutics, Inc.’s PE Ratio is greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Design Therapeutics, Inc. (-5.23), less than Ikena Oncology, Inc. (-1.22), greater than Stoke Therapeutics, Inc. (-7.92), greater than Edgewise Therapeutics, Inc. (-14.14), greater than Decibel Therapeutics, Inc. (-1.94), greater than Celcuity Inc. (-7.01), greater than C4 Therapeutics, Inc. (-3.44), less than Talaris Therapeutics, Inc. (-0.20), less than Adicet Bio, Inc. (-0.98), greater than Cullinan Oncology, Inc. (-6.96), less than Vor Biopharma Inc. (-0.53), greater than Third Harmonic Bio, Inc. (-26.95), less than Passage Bio, Inc. (-0.57), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than Eliem Therapeutics, Inc. (-3.49), greater than Molecular Partners AG (-2.67), greater than MediciNova, Inc. (-12.61), greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Champions Oncology, Inc. (-7.94), greater than Cyteir Therapeutics, Inc. (-3.52),
Company | PE Ratio | Market cap |
---|---|---|
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-1.22 | $81.56M | |
-7.92 | $773.92M | |
-14.14 | $1.64B | |
-1.94 | $123.37M | |
-7.01 | $557.67M | |
-3.44 | $374.42M | |
-0.20 | $116.44M | |
-0.98 | $121.95M | |
-6.96 | $1.04B | |
-0.53 | $62.11M | |
-26.95 | $493.17M | |
-0.57 | $43.48M | |
-4.23 | $250.26M | |
-3.49 | $495.57M | |
-2.67 | $182.90M | |
-12.61 | $103.00M | |
-4.99 | $46.68M | |
-7.94 | $57.77M | |
-3.52 | $108.71M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Werewolf Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Werewolf Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Werewolf Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Werewolf Therapeutics, Inc. (HOWL)?
What is the highest PE Ratio for Werewolf Therapeutics, Inc. (HOWL)?
What is the 3-year average PE Ratio for Werewolf Therapeutics, Inc. (HOWL)?
What is the 5-year average PE Ratio for Werewolf Therapeutics, Inc. (HOWL)?
How does the current PE Ratio for Werewolf Therapeutics, Inc. (HOWL) compare to its historical average?